Filing Flows

Filing Flows › Companies › Mangoceuticals › Cash flow

Mangoceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$261K in Q2 2026 · −$3.9M over twelve months

Operating cash flow−$261K
Free cash flow−$261K

Analysis

In Q2 2026, Mangoceuticals generated −$261K of operating cash flow. That is $996K more than in Q2 2025 (−$1.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$3.9M; the largest uses were operating cash flow ($3.9M); besides operations, cash came from shares issued ($3.8M), other financing ($210K); the cash balance rose by $128K.

Operating cash flow was −$261K against net income of −$1.3M. The largest differences: payables +$360K, depreciation & amortization +$280K, stock-based pay +$12K.

Free cash flow

Mangoceuticals: free cash flow by quarterMangoceuticals: free cash flow by quarter−$1.2MQ3 2024−$1.1MQ4 2024−$2.3MQ1 2025−$1.3MQ2 2025−$1.2MQ3 2025−$1.1MQ4 2025−$1.3MQ1 2026−$261KQ2 2026
Operating cash flow less capital spending.
Mangoceuticals: operating cash flow against capital spendingMangoceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$1.2M$0Q3 2024−$1.1M$0Q4 2024−$2.3M$0Q1 2025−$1.3M$0Q2 2025−$1.2M$0Q3 2025−$1.1M$0Q4 2025−$1.3M$0Q1 2026−$261K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$261K, Capital spending $0.

Capital allocation, year by year

Mangoceuticals: where the cash came from (up) and went (down), by fiscal yearMangoceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2022: Operating cash flow −$1.3MFY2022: Shares issued $2.0MFY2022: Capital spending −$43K$2.0MFY2022FY2023: Operating cash flow −$7.0MFY2023: Shares issued $6.2MFY2023: Capital spending −$4K$6.2MFY2023FY2024: Operating cash flow −$4.9MFY2024: Net borrowing $150KFY2024: Shares issued $4.0MFY2024: Asset sales $65K$4.2MFY2024FY2025: Operating cash flow −$5.9MFY2025: Net borrowing $500KFY2025: Shares issued $4.7M$5.2MFY2025
Over these 4 years operating cash flow totalled −$19.1M; the largest uses were operating cash flow ($19.1M) and capital spending ($47K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$229K
Debtnone
Net cash$229K
Cash runway1 month

Mangoceuticals is burning cash: its operations consume cash, a free cash flow of −$3.9M a year at the current rate against $229K of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

Mangoceuticals: sources (+) and uses (−) of cash, Q2 2026Mangoceuticals: sources (+) and uses (−) of cash, Q2 2026Not reconciled$317KOperating cash flow−$261KCash drawn (+) / kept (−)−$54KExchange rates−$2K
Mangoceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Mangoceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$3.9MShares issued$3.8MOther financing$210KCash drawn (+) / kept (−)−$128KExchange rates−$3K

From profit to cash

Mangoceuticals: net income to operating cash flow, Q2 2026Mangoceuticals: net income to operating cash flow, Q2 2026Net income−$1.3MDepreciation & amortization$280KStock-based pay$12KPayables$360KIncome taxes payable$3KOperating cash flow−$261K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$261K——−$54K−$261K
Q1 2026−$1.3M——$1.3M−$1.3M
Q4 2025−$1.1M—$2.2M−$1.0M−$1.1M
Q3 2025−$1.2M—$1.3M−$380K−$1.2M
Q2 2025−$1.3M—−$619K−$25K−$1.3M
Q1 2025−$2.3M—$1.8M−$18K−$2.3M
Q4 2024−$1.1M−$38K$1.2M$15K−$1.1M
Q3 2024−$1.2M—$750K$416K−$1.2M

Mangoceuticals: income statement and cash flow

Mangoceuticals, Q2 2026: revenue $69K (-59% year over year). The chart follows the revenue to costs, profit and cash.

Mangoceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.